Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Active:	Yes
Cancer Type:	Leukemia Lymphoma	NCT ID:	NCT05776134
Trial Phases:		Protocol IDs:	KT-US-472-0141 (primary)
Eligibility:	18 Years and older (Adult, Older Adult ), Male and Female	Study Type:
Study Sponsor:	Gilead Sciences (Kite, A Gilead Company)
NCI Full Details:	https://clinicaltrials.gov/study/NCT05776134?tab=table

Summary

The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

Biological: Brexucabtagene Autoleucel
- A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
- Other Names:
  - Tecartus™

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.